cetuximab信息详情
西妥昔单抗
The results of two randomized trials looking at the combination of bevacizumab and cetuximab are awaited.───两项对联合应用贝伐单抗和西妥昔单抗的随机试验结果还须等待。
But these drugs called EGFR inhibitors, such as cetuximab, have not been very effective against colon cancer.───但这些称为EGFR抑制因子如西妥昔单抗的药物对结肠癌的治疗还不是很有效。
use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland.───法国及美国应用西妥昔单抗治疗直肠结肠癌最多，而芬兰最低。
The new study aimed to see if addition of the drug cetuximab, also known as Erbitux, would help patients even more.───最新的研究看出如果加用西妥昔单抗（又名爱比妥）可以明显增加这种手术切除的优势。
Objective As EGFR inhibitor, Cetuximab has been widely used in several solid tumors, and has perfect therapeutic effect and security.───目的作为EGFR抑制剂，西妥昔单抗在多种实体瘤中应用日益广泛，显示出良好的疗效和安全性。
The pharmacologic actions of cetuximab and its clinical evaluation are reviewed in this paper.───本文综述了西妥昔单抗的药理作用及临床评价。
Biopsies and plasma samples were taken before treatment, after cetuximab but before CRT, and at the time of surgery.───治疗前先行活组织检查和血浆样本的采集，西妥昔单抗应用之前，CRT之前，即手术的时机。
The use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland.───法国及美国应用西妥昔单抗治疗直肠结肠癌最多，而芬兰最低。
The use of bevacizumab (as well as cetuximab) for maintenance remains unproven, however.───贝伐单抗（以及西妥昔单抗）对维持治疗仍无提高。